Expression of miR-224-5p Is Associated With the Original Cisplatin Resistance of Ovarian Papillary Serous Carcinoma

Oncology Reports - Greece
doi 10.3892/or.2014.3311
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Altered eIF6 and Dicer Expression Is Associated With Clinicopathological Features in Ovarian Serous Carcinoma Patients

Modern Pathology
Forensic MedicinePathology
2008English

LncRNA NEAT1 Enhances the Resistance of Anaplastic Thyroid Carcinoma Cells to Cisplatin by Sponging miR‑9‑5p and Regulating SPAG9 Expression

International Journal of Oncology
Cancer ResearchOncology
2019English

Distinct Gene Expression Profiles Associated With Clinical Outcomes in Patients With Ovarian Clear Cell Carcinoma and High-Grade Serous Ovarian Carcinoma

Journal of Ovarian Research
GynecologyOncologyObstetrics
2020English

Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma

PLoS ONE
Multidisciplinary
2011English

Hypermethylation of the microRNA miR-124, miR-125b, miR-127, and miR-129 in Ovarian Carcinoma Is Involved in Suppression of Their Expression and Associated With Both the Development and Progression of Ovarian Cancer

Almanac of Clinical Medicine
2019English

Downregulation of miR-194-5p Induces Paclitaxel Resistance in Ovarian Cancer Cells by Altering MDM2 Expression

Oncotarget
Oncology
2019English

Cisplatin Resistance in an Ovarian Carcinoma Is Associated With a Defect in Programmed Cell Death Control Through XIAP Regulation

Oncology Research
MedicineCancer ResearchOncology
2003English

Increased CD70 Expression Is Associated With Clinical Resistance to Cisplatin-Based Chemotherapy and Poor Survival in Advanced Ovarian Carcinomas

OncoTargets and Therapy
OncologyPharmacology
2013English

VISTA Expression Is Associated With a Favorable Prognosis in Patients With High-Grade Serous Ovarian Cancer

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy